These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23619367)

  • 21. GPR109A and vascular inflammation.
    Chai JT; Digby JE; Choudhury RP
    Curr Atheroscler Rep; 2013 May; 15(5):325. PubMed ID: 23526298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of niacin on atherosclerosis and vascular function.
    Ruparelia N; Digby JE; Choudhury RP
    Curr Opin Cardiol; 2011 Jan; 26(1):66-70. PubMed ID: 21045681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Niacin: the evidence, clinical use, and future directions.
    Villines TC; Kim AS; Gore RS; Taylor AJ
    Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of GPR109a Signaling in Niacin Induced Effects on Fed and Fasted Hepatic Metabolism.
    Geisler CE; Miller KE; Ghimire S; Renquist BJ
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niacin as antidyslipidemic drug.
    Julius U
    Can J Physiol Pharmacol; 2015 Dec; 93(12):1043-54. PubMed ID: 26370906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosis.
    Feng Y; Lievens J; Jacobs F; Hoekstra M; Van Craeyveld E; Gordts SC; Snoeys J; De Geest B
    Cardiovasc Res; 2010 Nov; 88(2):376-85. PubMed ID: 20562425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
    Lukasova M; Hanson J; Tunaru S; Offermanns S
    Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
    Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
    Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.
    Goel H; Dunbar RL
    Curr Atheroscler Rep; 2016 Apr; 18(4):17. PubMed ID: 26932224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy for dyslipidaemia--current therapies and future agents.
    Bays H; Stein EA
    Expert Opin Pharmacother; 2003 Nov; 4(11):1901-38. PubMed ID: 14596646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
    Sakai T; Kamanna VS; Kashyap ML
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1783-9. PubMed ID: 11701466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
    Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
    Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S
    Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells.
    Siripurkpong P; Na-Bangchang K
    J Nutr Biochem; 2009 Apr; 20(4):261-8. PubMed ID: 18602814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study.
    Phan BA; Muñoz L; Shadzi P; Isquith D; Triller M; Brown BG; Zhao XQ
    Am J Cardiol; 2013 Feb; 111(3):352-5. PubMed ID: 23168285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin.
    Rubic T; Trottmann M; Lorenz RL
    Biochem Pharmacol; 2004 Feb; 67(3):411-9. PubMed ID: 15037193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.